[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355954-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355954-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","fc-engineering-of-a-fully-humanized-anti-cd147-monoclonal-antibody-enhances-adcc-against-t-cell-acute-lymphoblastic-leukemia-and-t-lymphoblastic-lymphoma","Fc engineering of a fully humanized anti-CD147 monoclonal antibody enhances ADCC against T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma","","T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma are aggressive hematologic cancers with limited targeted options and poor outcomes. CD147, a multifunctional transmembrane glycoprotein highly expressed in these malignancies, is linked to tumor progression and immune evasion, making it an immunotherapy target. This study evaluates HuM6-1B9-5M, a fully humanized Fc-engineered anti-CD147 monoclonal antibody designed to strengthen ADCC through five Fc mutations. Expression in HEK293T cells preserved CD147 binding, and PBMC-based assays showed enhanced ADCC against T-ALL and T-LBL cell models versus wild-type.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/fc-engineering-of-a-fully-humanized-anti-cd147-monoclonal-antibody-enhances-adcc-against-t-cell-acute-lymphoblastic-leukemia-and-t-lymphoblastic-lymphoma/355954/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/fc-engineering-of-a-fully-humanized-anti-cd147-monoclonal-antibody-enhances-adcc-against-t-cell-acute-lymphoblastic-leukemia-and-t-lymphoblastic-lymphoma/355954.png","ImageObject",300,407,{"name":42,"@type":43},"Mary Man","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why target CD147 for T-ALL and T-LBL immunotherapy?","Question",{"text":63,"@type":64},"CD147 is frequently upregulated in T-cell malignancies and supports tumor progression and immune evasion. Its involvement in oncogenic processes makes it a promising target for antibody-based immunotherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the Fc-engineered anti-CD147 antibody HuM6-1B9-5M designed?",{"text":68,"@type":64},"HuM6-1B9-5M was fully humanized and engineered by introducing five Fc mutations (L235V/F243L/R292P/Y300L/P396L) to enhance ADCC.",{"name":70,"@type":61,"acceptedAnswer":71},"What experimental evidence supports that Fc mutations improved ADCC activity?",{"text":72,"@type":64},"Biolayer interferometry showed the mutations did not reduce antigen-binding affinity, and PBMC effector-cell functional assays demonstrated enhanced ADCC by HuM6-1B9-5M compared with the wild-type antibody against Jurkat and SupT1 models.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355954,1790171011,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nFc engineering of a fully humanized anti-CD147 monoclonal antibody enhancesADCC against T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma  \nZaw Ye Htet1,2, Thanathat Pamonsupornwichit2, Kanokporn Sornsuwan2,3, Natsima Viriyaadhammaa2,6, Phatcharida Jantaree4,5, UmpaYasamut2,6, Nutjeera Intasai1,2􀀍 & ChatchaiTayapiwatana2,6􀀍  \nT-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) are aggressive hematologic malignancies with limited targeted treatment options and poor clinical outcomes across all age groups. CD147 is a multifunctional transmembrane glycoprotein that is highly expressed in various cancers, including T-cell leukemia and lymphoma. Its involvement in tumor progression and immune evasion makes CD147 a promising target for cancer immunotherapy. Monoclonal antibodybased immunotherapy can eliminate tumor cells not only by blocking oncogenic signaling pathways but also by engaging immune effector cells through antibody-dependent cellular cytotoxicity (ADCC) . Enhancing ADCC has therefore emerged as a crucial strategy to enhance the therapeutic efficacy of anti-cancer antibodies. This study aimed to evaluate the functional activity of a fully humanized Fcengineered anti-CD147 monoclonal antibody, HuM6-1B9-5M, which was designed to enhance ADCC by introducing five Fc mutations (L235V/F243L/R292P/Y300L/P396L) . HuM6-1B9-5M was successfully expressed in HEK293T cells and retained CD147 binding activity and specificity comparable to those of the parental antibody. Biolayer interferometry against CD147 confirmed that Fc substitutions did not adversely affect antigen-binding affinity. Functional assays using PBMC effector cells demonstrated enhanced ADCC activity of HuM6-1B9-5M relative to the wild-type antibody (HuM6-1B9-WT) against Jurkat and SupT1 cell lines, representing T-ALL andT-LBL models, respectively.  \nKeywords T-ALL, T-LBL, CD147, Fc engineering, Humanized antibody, ADCC  \nT-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) are heterogeneous T-cell hematologic malignancies that arise from the clonal expansion of T-cell precursors and are strongly associated with poorer prognoses than their B-cell counterparts1–3. T-ALL/LBL are characterized by uncontrolled proliferation of immature T-lymphoblasts and their localization to different anatomical sites, mainly in the bone marrow, mediastinum, and lymphoid organs. This dissemination frequently leads to central nervous system (CNS) involvement, which represents a major site of relapse4–6. Despite significant advances in monoclonal antibody (mAb)-based therapies for leukemia, effective targeted treatments for T-ALL/LBL remain limited, leaving patients largely dependent on intensive, non-specific chemotherapy regimens with substantial toxicity  \n1Division of Clinical Microscopy, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand. 2Center of Biomolecular Therapy and Diagnostic, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand. 3Office of Research Administration, Chiang Mai University, Chiang Mai 50200, Thailand. 4Center of Multidisciplinary Technology for Advanced Medicine (CMUTEAM), Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. 5Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. 6Division of Clinical Immunology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand. 􀀍 email: [nutjeera.in@cmu.ac.th](nutjeera.in@cmu.ac.th); [chatchai.t@cmu.ac.th](chatchai.t@cmu.ac.th)  \nand adverse effects7. Therefore, there remains a need for more effective and targeted treatment approaches for T-ALL/LBL.  \nThe cluster of differentiation 147 (CD147), also known as extracellular matrix meta","cbCaimDO4txt5iuK","https://ap.wps.com/l/cbCaimDO4txt5iuK","pdf",2275982,14,"English","# Background\n## CD147 as an immunotherapy target\n# Study Aim and Antibody Design\n## HuM6-1B9-5M and Fc mutations\n# Expression and Binding Validation\n## HEK293T expression\n## Biolayer interferometry\n# Functional Assessment\n## PBMC ADCC assays\n## Jurkat and SupT1 cell models","[{\"question\":\"Why target CD147 for T-ALL and T-LBL immunotherapy?\",\"answer\":\"CD147 is frequently upregulated in T-cell malignancies and supports tumor progression and immune evasion. Its involvement in oncogenic processes makes it a promising target for antibody-based immunotherapy.\"},{\"question\":\"How was the Fc-engineered anti-CD147 antibody HuM6-1B9-5M designed?\",\"answer\":\"HuM6-1B9-5M was fully humanized and engineered by introducing five Fc mutations (L235V/F243L/R292P/Y300L/P396L) to enhance ADCC.\"},{\"question\":\"What experimental evidence supports that Fc mutations improved ADCC activity?\",\"answer\":\"Biolayer interferometry showed the mutations did not reduce antigen-binding affinity, and PBMC effector-cell functional assays demonstrated enhanced ADCC by HuM6-1B9-5M compared with the wild-type antibody against Jurkat and SupT1 models.\"}]","Fc engineering of a fully humanized anti-CD147 monoclonal antibody enhances ADCC against T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma | PDF",1790121950,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb4cf78d171ed451d4a09dcfdaad6a62.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/974894f5e567dfd0ebd50c9339798efc.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/75d5f7d548795c256838567b51aff5f8.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97718faf330dc2beb45768990529eed9.webp",980,1287]